Bio-Techne (NASDAQ:TECH – Get Free Report) and Quantum-Si (NASDAQ:QSI – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.
Institutional & Insider Ownership
98.9% of Bio-Techne shares are owned by institutional investors. Comparatively, 39.9% of Quantum-Si shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by insiders. Comparatively, 22.0% of Quantum-Si shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Bio-Techne and Quantum-Si’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bio-Techne | 13.95% | 13.00% | 10.57% |
| Quantum-Si | -6,729.80% | -44.72% | -41.26% |
Analyst Ratings
This is a summary of recent recommendations and price targets for Bio-Techne and Quantum-Si, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bio-Techne | 1 | 14 | 1 | 1 | 2.12 |
| Quantum-Si | 1 | 1 | 3 | 0 | 2.40 |
Bio-Techne presently has a consensus price target of $69.00, indicating a potential downside of 5.16%. Quantum-Si has a consensus price target of $2.50, indicating a potential upside of 153.04%. Given Quantum-Si’s stronger consensus rating and higher possible upside, analysts plainly believe Quantum-Si is more favorable than Bio-Techne.
Earnings & Valuation
This table compares Bio-Techne and Quantum-Si”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bio-Techne | $1.23 billion | 9.31 | $181.86 million | $1.09 | 66.75 |
| Quantum-Si | $2.44 million | 88.98 | -$101.34 million | ($0.39) | -2.53 |
Bio-Techne has higher revenue and earnings than Quantum-Si. Quantum-Si is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Bio-Techne has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Quantum-Si has a beta of 3.26, indicating that its share price is 226% more volatile than the S&P 500.
Summary
Bio-Techne beats Quantum-Si on 9 of the 15 factors compared between the two stocks.
About Bio-Techne
Bio-Techne is a life sciences company that develops and supplies products and services used in biological research, drug development, and clinical diagnostics. Its offerings include proteins, antibodies, immunoassays, and small molecules, as well as instruments and analytical tools for studying cells and biological processes. The company also provides technologies for protein analysis, molecular diagnostics, and spatial biology. Its portfolio includes products and services associated with brands such as R&D Systems, Tocris, ProteinSimple, and Advanced Cell Diagnostics.
About Quantum-Si
Quantum-Si is a life sciences technology company developing tools for protein sequencing and proteomics research. Its platform uses semiconductor technology and single-molecule detection to analyze proteins, with the aim of making protein-level information more accessible to researchers. The company’s offerings include the Platinum benchtop instrument, along with consumables, reagents and software used to prepare, run and analyze samples. Quantum-Si’s products are designed for research applications in areas such as drug discovery and biological research.
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.
